ArticleCalcified tissue international2026
Capsanthin Attenuates Osteoporosis by Targeting the Urotensin II Receptor Pathway to Inhibit Oxidative Stress and NLRP3 Inflammasome Activation.
Article in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although multiple pharmacological options exist for postmenopausal osteoporosis (PMOP), the pursuit of better-tolerated and naturally derived alternatives remains active. This study evaluates the therapeutic potential of capsanthin (Cap), the principal carotenoid in red chili peppers, against estrogen deficiency-induced bone loss. Ovariectomized (OVX) mice were treated with Cap (5-20 mg/kg/day) for 12 weeks. Bone mass and microarchitecture were assessed by micro-computed tomography (µCT) and biomechanical testing. Serum markers of bone turnover and inflammation were measured by ELISA. Network pharmacology and molecular docking were employed to predict core targets, and the involvement of the urotensin II (UII) system and NLRP3 inflammasome was investigated using specific inhibitors in vitro. Cap treatment at 10-20 mg/kg significantly attenuated OVX-induced bone loss, increasing bone mineral density (BMD), improving trabecular microstructure (elevated BV/TV and Tb.Th, reduced Tb.Sp), and enhancing bone strength. Cap promoted osteogenic activity and suppressed osteoclastic resorption. Network analysis identified the UII signaling pathway as a key potential target, and molecular docking confirmed strong binding between Cap and UII. Mechanistically, Cap inhibited the UII/UT axis, leading to reduced oxidative stress (decreased ROS/H
Indexed as
Identifiers
42410254What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.